A new publication on the safety and high tolerability of the oncolytic virus Rigvir December 2, 2022

Oncolytic virus preclinical toxicology studies (Journal of Applied Toxicology)

The Rigvir virus continues to please us with new publications about its safety and harmlessness.

The search for treatments as safe as possible is a priority in medical care, especially in cancer care, where therapies often go hand in hand with severe side effects. Oncolytic virotherapy is promising in both safety and efficacy. This article summarizes the preclinical toxicology studies of several oncolytic viruses in different stages of development. Considering that the adverse events were mostly minor and reversible, it is concluded that oncolytic viruses have low toxicity and good tolerability. Regarding basic toxicology studies, Rigvir, even at the highest dose tested, showed high tolerability and did not induce any severe adverse event, unlike some of the genetically modified viruses.

View full article: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jat.4408